Caricamento...
A CRITICAL ASSESSMENT OF EDARAVONE ACUTE ISCHEMIC STROKE EFFICACY TRIALS: IS EDARAVONE AN EFFECTIVE NEUROPROTECTIVE THERAPY?
IMPORTANCE OF THE FIELD: Edaravone (Radicut®) is a free radical scavenger marketed in Japan by Mitsubishi Tanabe Pharma Corporation to treat acute ischemic stroke (AIS) patients presenting within 24 hours of the attack. Injectable edaravone ampoules (30mg b.i.d, i.v., 14 days) were first approved on...
Salvato in:
| Autore principale: | |
|---|---|
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
2010
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2891515/ https://ncbi.nlm.nih.gov/pubmed/20491547 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1517/14656566.2010.493558 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|